BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 33063681)

  • 1. Targeted Next-Generation Sequencing of Plasma Cell-Free DNA in Korean Patients with Hepatocellular Carcinoma.
    Chae H; Sung PS; Choi H; Kwon A; Kang D; Kim Y; Kim M; Yoon SK
    Ann Lab Med; 2021 Mar; 41(2):198-206. PubMed ID: 33063681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
    Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
    Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted Next-Generation Sequencing Combined With Circulating-Free DNA Deciphers Spatial Heterogeneity of Resected Multifocal Hepatocellular Carcinoma.
    Lin J; Zhao S; Wang D; Song Y; Che Y; Yang X; Mao J; Xie F; Long J; Bai Y; Yang X; Zhang L; Bian J; Lu X; Sang X; Pan J; Wang K; Zhao H
    Front Immunol; 2021; 12():673248. PubMed ID: 34211467
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic Mutations in Circulating Cell-Free DNA and Risk for Hepatocellular Carcinoma in Hispanics.
    Jiao J; Sanchez JI; Thompson EJ; Mao X; McCormick JB; Fisher-Hoch SP; Futreal PA; Zhang J; Beretta L
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of mutations in circulating cell-free tumour DNA as a biomarker in hepatocellular carcinoma.
    Howell J; Atkinson SR; Pinato DJ; Knapp S; Ward C; Minisini R; Burlone ME; Leutner M; Pirisi M; Büttner R; Khan SA; Thursz M; Odenthal M; Sharma R
    Eur J Cancer; 2019 Jul; 116():56-66. PubMed ID: 31173963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
    Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
    JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma.
    Coto-Llerena M; Benjak A; Gallon J; Meier MA; Boldanova T; Terracciano LM; Ng CKY; Piscuoglio S
    JCO Precis Oncol; 2022 Mar; 6():e2100335. PubMed ID: 35263170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial.
    Alunni-Fabbroni M; Rönsch K; Huber T; Cyran CC; Seidensticker M; Mayerle J; Pech M; Basu B; Verslype C; Benckert J; Malfertheiner P; Ricke J
    J Transl Med; 2019 Oct; 17(1):328. PubMed ID: 31570105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of molecular barcode sequencing for the detection of low-frequency variants in circulating tumour DNA from hepatocellular carcinoma.
    Lee HW; Kim E; Cho KJ; Park HJ; Seo J; Lee H; Baek E; Choi JR; Han KH; Lee ST; Park JY
    Liver Int; 2022 Oct; 42(10):2317-2326. PubMed ID: 35776657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post-treatment cell-free DNA as a predictive biomarker in molecular-targeted therapy of hepatocellular carcinoma.
    Nakatsuka T; Nakagawa H; Hayata Y; Wake T; Yamada T; Nishibatake Kinoshita M; Nakagomi R; Sato M; Minami T; Uchino K; Enooku K; Kudo Y; Tanaka Y; Kishikawa T; Otsuka M; Tateishi R; Koike K
    J Gastroenterol; 2021 May; 56(5):456-469. PubMed ID: 33712873
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of ultra-deep targeted sequencing of plasma DNA identifies driver mutations in hepatocellular carcinoma.
    Labgaa I; Villacorta-Martin C; D'Avola D; Craig AJ; von Felden J; Martins-Filho SN; Sia D; Stueck A; Ward SC; Fiel MI; Mahajan M; Tabrizian P; Thung SN; Ang C; Friedman SL; Llovet JM; Schwartz M; Villanueva A
    Oncogene; 2018 Jul; 37(27):3740-3752. PubMed ID: 29628508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study.
    Ng CKY; Di Costanzo GG; Tosti N; Paradiso V; Coto-Llerena M; Roscigno G; Perrina V; Quintavalle C; Boldanova T; Wieland S; Marino-Marsilia G; Lanzafame M; Quagliata L; Condorelli G; Matter MS; Tortora R; Heim MH; Terracciano LM; Piscuoglio S
    Ann Oncol; 2018 May; 29(5):1286-1291. PubMed ID: 29509837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
    Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
    J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutation profile and its correlation with clinicopathology in Chinese hepatocellular carcinoma patients.
    Wang S; Shi H; Liu T; Li M; Zhou S; Qiu X; Wang Z; Hu W; Guo W; Chen X; Guo H; Shi X; Shi J; Zang Y; Cao J; Wu L
    Hepatobiliary Surg Nutr; 2021 Apr; 10(2):172-179. PubMed ID: 33898558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ser-249 TP53 and CTNNB1 mutations in circulating free DNA of Egyptian patients with hepatocellular carcinoma versus chronic liver diseases.
    Hosny G; Farahat N; Tayel H; Hainaut P
    Cancer Lett; 2008 Jun; 264(2):201-8. PubMed ID: 18313840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. eVIDENCE: a practical variant filtering for low-frequency variants detection in cell-free DNA.
    Mizuno K; Akamatsu S; Sumiyoshi T; Wong JH; Fujita M; Maejima K; Nakano K; Ono A; Aikata H; Ueno M; Hayami S; Yamaue H; Chayama K; Inoue T; Ogawa O; Nakagawa H; Fujimoto A
    Sci Rep; 2019 Oct; 9(1):15017. PubMed ID: 31641155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessments of TP53 and CTNNB1 gene hotspot mutations in circulating tumour DNA of hepatitis B virus-induced hepatocellular carcinoma.
    Kumar S; Nadda N; Quadri A; Kumar R; Paul S; Tanwar P; Gamanagatti S; Dash NR; Saraya A; Shalimar ; Nayak B
    Front Genet; 2023; 14():1235260. PubMed ID: 37593116
    [No Abstract]   [Full Text] [Related]  

  • 18. Next-Generation Sequencing of Circulating Tumor DNA Reveals Frequent Alterations in Advanced Hepatocellular Carcinoma.
    Ikeda S; Tsigelny IF; Skjevik ÅA; Kono Y; Mendler M; Kuo A; Sicklick JK; Heestand G; Banks KC; Talasaz A; Lanman RB; Lippman S; Kurzrock R
    Oncologist; 2018 May; 23(5):586-593. PubMed ID: 29487225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
    Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
    World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
    Kawai-Kitahata F; Asahina Y; Tanaka S; Kakinuma S; Murakawa M; Nitta S; Watanabe T; Otani S; Taniguchi M; Goto F; Nagata H; Kaneko S; Tasaka-Fujita M; Nishimura-Sakurai Y; Azuma S; Itsui Y; Nakagawa M; Tanabe M; Takano S; Fukasawa M; Sakamoto M; Maekawa S; Enomoto N; Watanabe M
    J Gastroenterol; 2016 May; 51(5):473-86. PubMed ID: 26553052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.